Press Release Service

Ensoma Announces $85 Million Financing and Agreement to Acquire Twelve Bio to Advance Portfolio of In Vivo Engineered Cellular Medicines

Ensoma Announces $85 Million Financing and Agreement to Acquire Twelve Bio to Advance Portfolio of In Vivo Engineered Cellular Medicines.

- Jan. 5, 2023
News

BOSTON--(BUSINESS WIRE)--Ensoma, a genomic medicines company developing one-time in vivo treatments that precisely engineer any cell of the hematopoietic system, today announced the completion of an $85 million financing. Proceeds will enable Ensoma to advance the development of its Engenious™ in vivo engineered cell therapy platform and accelerate its pipeline of genomic medicines for immuno-oncology and other therapeutic applications. The company also announced it has entered into a definitive agreement to acquire Twelve Bio ApS, a gene editing company pioneering the therapeutic application of next-generation CRISPR-Cas technology.

Read the PR here.

Tags

HashtagArticleHashtagNewsHashtagPress Release ServiceHashtagTwelve Bio

News: Ensoma Announces $85 Million Financing and Agreement to Acquire Twelve Bio to Advance Portfolio of In Vivo Engineered Cellular Medicines
News: Ensoma Announces $85 Million Financing and Agreement to Acquire Twelve Bio to Advance Portfolio of In Vivo Engineered Cellular Medicines
CLINICAL TRIALS
Hereditary Angioedema, HAE, (NCT06262399)
Sponsors:
Intellia Therapeutics
IND Enabling
Phase I
Phase II
Phase III
Renal Cell Carcinoma, RCC, (NCT06245915)
Sponsors:
Arsenal Biosciences, Inc.
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Solid Tumors, (NCT06237881)
Sponsors:
M.D. Anderson Cancer Center
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
View all clinical trials
close
Search CRISPR Medicine